Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactions

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 2, 2013, Pages 388-396

  Nishimura, Toshiko ^a   Hu, Yajing ^a   Wu, Manhong ^a   Pham, Edward ^b   Suemizu, Hiroshi ^c   Elazar, Menashe ^b   Liu, Michael ^b   Idilman, Ramazan ^e   Yurdaydin, Cihan ^e   Angus, Peter ^f   Stedman, Catherine ^g   Murphy, Brian ^h   Glenn, Jeffrey ^b   Nakamura, Masato ^c   Nomura, Tatsuji ^c   Chen, Yuan ^d   Zheng, Ming ^a   Fitch, William L ^a   Peltz, Gary ^a  

^a Department of Anesthesia ^*  (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^d GENENTECH INC   (United States)

^e ANKARA UNIVERSITY   (Turkey)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY OF OTAGO   (New Zealand)

^h Eiger BioPharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLEMIZOLE; DRUG METABOLITE; RITONAVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CHIMERA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; MALE; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SINGLE DRUG DOSE;

ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CYTOCHROME P-450 CYP3A; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INHIBITORS; HALF-LIFE; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; LIVER; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSOMES, LIVER; PREDICTIVE VALUE OF TESTS; RATS; RITONAVIR; SPECIES SPECIFICITY; TRANSPLANTATION CHIMERA; VIRUS REPLICATION;

EID: 84872743384     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.198697     Document Type: Article

References (38)

1. Anderson S, Luffer-Atlas D, and Knadler MP (2009) Predicting circulating human metabolites: how good are we? Chem Res Toxicol 22:243-256.
2. Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E, Strom S, Kay MA, Finegold M, and Grompe M (2007) Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 25:903-910. (Pubitemid 47236918)
3. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, and Boparai N, et al.. (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207-1217.
4. Bissig K-D, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV, and Verma IM (2010) Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 120:650-653.
5. Bode C (2010) The nasty surprise of a complex drug-drug interaction. Drug Discov Today 15:391-395.
6. Chen AA, Thomas DK, Ong LL, Schwartz RE, Golub TR, and Bhatia SN (2011) Humanized mice with ectopic artificial liver tissues. Proc Natl Acad Sci USA 108: 11842-11847.
7. Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, and Bu HZ, et al. (2009) Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357-3678.
8. de Jong YP, Rice CM, and Ploss A (2010) New horizons for studying human hepatotropic infections. J Clin Invest 120:650-653.
9. De Serres M, Bowers G, Boyle G, Beaumont C, Castellino S, Sigafoos J, Dave M, Roberts A, Shah V, and Olson K, et al. (2011) Evaluation of a chimeric (uPA1/1) /SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 41:464-475.
10. Einav S, Gerber D, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, Glenn JS, and Quake SR (2008) Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol 26:1019-1027.
11. Einav S, Sobol HD, Gehrig E, and Glenn JS (2010) The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis 202:65-74.
12. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, and Meier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69: 223-231. (Pubitemid 32382504)
13. Guengerich FP and MacDonald JS (2007) Applying mechanisms of chemical toxicity to predict drug safety. Chem Res Toxicol 20:344-369. (Pubitemid 46548682)
14. Guo Y, Lu P, Farrell E, Zhang X, Weller P, Monshouwer M, Wang J, Liao G, Zhang Z, and Hu S, et al. (2007) In silico and in vitro pharmacogenetic analysis in mice. Proc Natl Acad Sci USA 104:17735-17740. (Pubitemid 350210904)
15. Guo Y, Lu P, Farrell E, Zhang X, Weller P, Monshouwer M, Wang J, Liao G, Zhang Z, and Hu S, et al. (2006) In silico pharmacogenetics of warfarin metabolism. Nat Biotechnol 24:531-536.
16. Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, Wakui M, Ito M, Suematsu M, Peltz G, Nakamura M, and Suemizu H, et al. (2011) The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 405:405-410.
17. Hsu A, Granneman GR, and Bertz RJ (1998) Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275-291. (Pubitemid 28491214)
18. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, and Tsuji K, et al. (2002) NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100:3175-3182. (Pubitemid 35217065)
19. Kamimura H, Nakada N, Suzuki K, Mera A, Souda K, Murakami Y, Tanaka K, Iwatsubo T, Kawamura A, and Usui T (2010) Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet 25:223-235.
20. Katoh M, Sawada T, Soeno Y, Nakajima M, Tateno C, Yoshizato K, and Yokoi T (2007) In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci 96:428-437. (Pubitemid 46363572)
21. Katoh M and Yokoi T (2007) Application of chimeric mice with humanized liver for predictive ADME. Drug Metab Rev 39:145-157.
22. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294. (Pubitemid 35284253)
23. Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, and Evans DC (2009) Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem Res Toxicol 22:280-293.
24. Lootens L, Van Eenoo P, Meuleman P, Leroux-Roels G, and Delbeke FT (2009) The uPA(1/1)-SCID mouse with humanized liver as a model for in vivo metabolism of 4-androstene-3,17-dione. Drug Metab Dispos 37:2367-2374.
25. Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, Roskams T, and Leroux-Roels G (2005) Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41: 847-856. (Pubitemid 40462948)
26. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, and Boparai N, et al. SPRINT-2 Investigators (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206.
27. Pozo OJ, Van Eenoo P, Deventer K, Lootens L, Grimalt S, Sancho JV, Hernández F, Meuleman P, Leroux-Roels G, and Delbeke FT (2009) Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry. Steroids 74:837-852.
28. Prichard MN and Shipman C, Jr. (1990) A three-dimensional model to analyze drugdrug interactions. Antiviral Res 14:181-205. (Pubitemid 20377558)
29. Prichard MN and Shipman C, Jr. (1996) Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir Ther 1:9-20. (Pubitemid 126690045)
30. Pritchard MN, Prichard LE, and Shipman C, Jr. (1992) MacSynergy II version 1.0 user's manual, University of Michigan, Ann Arbor.
31. Smith DA and Obach RS (2009) Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22:267-279.
32. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, and Hino H, et al. (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901-912. (Pubitemid 39129297)
33. Tscherne DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, and Rice CM (2006) Time- and temperature-dependent activation of hepatitis C virus for lowpH- triggered entry. J Virol 80:1734-1741. (Pubitemid 43228714)
34. Vyse TJ, Rozzo SJ, Drake CG, Izui S and Kotzin BL (1997) Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice. J Immunol 158:5566-5574. (Pubitemid 127681268)
35. Walker D, Brady J, Dalvie D, Davis J, Dowty M, Duncan JN, Nedderman A, Obach RS, and Wright P (2009) A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol 22: 1653-1662.
36. Xie HG, Wood AJ, Kim RB, Stein CM, and Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272. (Pubitemid 38499965)
37. Yoshizato K and Tateno C (2009) In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opin Drug Metab Toxicol 5:1435-1446.
38. Zhang L, Reynolds KS, Zhao P, and Huang SM (2010) Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol 243: 134-145.